January 28, 2013

Genzyme’s LEMTRADATM (alemtuzumab) Application for MS Accepted for Review by the FDA

Genzyme also Reports Very Encouraging Early Launch Indicators for AUBAGIO® (teriflunomide) in U.S.

 

Genzyme’s LEMTRADATM (alemtuzumab) Application for MS Accepted for Review by the FDA
Genzyme also Reports Very Encouraging Early Launch Indicators for AUBAGIO® (teriflunomide) in U.S.

Paris, France — January 28, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADATM (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS). The company also reported key highlights from the U.S. launch of once-daily, oral AUBAGIO (teriflunomide).